THE GLOBAL LEADER OF BOTULINUM TOXIN INDUSTRY
THE
NUMBERS
FRIST COMPANY IN KOREA
1
Medytox is first approved botulinum toxin company in Korea (KFDA). World’s fourth botulinum toxin manufacturing company.
THE ONLY COMPANY WORLDWIDE
3
Medytox is the only company worldwide that manufactures and provides 3 types of botulinum toxin products. (Neuronox, Innotox, Coretox)
TOP STOCK PRICE IN KOSDAQ
4
Since 2009 Medytox was listed on KOSDAQ, Medytox has achieved sustained growth, and is now 4th highest - priced company. Highest share price among pharmaceutical companies.
(2023. 6. 16 KOSDAQ)
R&D
20%
Ratio of R&D Investment to Sales is 20% in 2023.
Medytox completed phase 3 clinical trials of MT921, the world's first injection lypolysis based on cholic acid.
YEAR
23
Medytox was founded in 2000. Since the launch of botulinum toxin type A , Medytox has shown a dramatic growth.
EMPLOYEES
800
Medytox has over 800 employees and local subsidiaries in Japan, America and Thailand.
MDT International Inc.
Tel: 03-6452-9606 Fax: 03-6452-9608
10F Vort Shibadaimon, 2-6-6 Shibadaimon, Minato-ku,Tokyo 105-0012
© 2023 by MDT International. All rights reserved.
Medytox Centers
Medytox Global Business Center
Medytox Global Business Center (Gangnam, Seoul) focuses on maximizing synergy by managing each business unit and plays a role as a global business center by managing plants in Korea including Seoul, Suwon, Osong, and Ochang and overseas corporations in China, Japan, Thailand, Taiwan, and Hong Kong.
Medytox R&D Center
Medytox R&D Center (Gwanggyo) is a 13-story biolab (with 5 stories underground & 8 stories) equipped with state-of-the-art research facilities and world-class research infrastructure. The unique characteristic lies in constructing one-stop R&D system, in which one can do all possible research in one location to create innovative and noteworthy research outcomes.
Medytox Manufacturing Plants
Plant I
Medytox Plant I (Ochang), Korea’s first botulinum toxin type A manufacturing facility, is producing 60 billion KRW worth of botulinum toxin type A and 0.1 trillion KRW worth of hyaluronic acid filler annually.
Plant II
Medytox Plant II (Osong), designed to meet cGMP of US FDA and GMP standard of European EMA, can produce more than 500 billion KRW worth of botulinum toxin Type A product. Currently, it is operated as a production facility for new botulinum toxin type A to enter the advanced markets such as US, EU.
Plant III
Medytox Plant III (Osong), designed and built to produce annual sales 0.6 trillion KRW worth of botulinum toxin type A and 0.5 trillion KRW worth of filler product, is running to accommodate global product demands without any problems. In particular, the filler production department is US FDA’s cGMP and Europe EMA’s EU GMP compliant facility, which is planned to provide products using hyaluronic acid such as hyaluronic filler to the advanced markets such as the US and Europe.
Our Creative Founder
As a young global biopharmaceutical company established in 2000, we set a goal of entering the ‘Top 20 list of global biopharmaceutical companies’. Going forward, Medytox will strive to tackle the advanced markets and to directly penetrate and expand into the emerging markets. We will create meaningful performance with new businesses by increasing investment in R&D and pushing continuous commercialization.
Medytox Founder & CEO
Hyunho Jung
Doctor of Biology
KAIST
Seoul National University
US National Institutes of Health (NIH)
MDT International (Japan) CEO
Y.S Jang
Bachelor of Business Administration
Ritsumeikan APU (2nd class)
lang: ja, kr, en